Modern Risk Stratification of Acute Myeloid Leukemia in 2023: Integrating Established and Emerging Prognostic FactorsEleonora Boscaro, Marco Cerrano, Dario Ferrero et al.|Cancers|2023Cited by 35
Sorafenib in combination with intensive chemotherapy for relapsed or refractory FLT3-ITD positive acute myeloid leukemia: A two centers experienceIrene Urbino, Marco Cerrano, Carolina Secreto et al.|Leukemia Research|2023Cited by 2
Arsenic trioxide neurotoxicity in acute promyelocytic leukemia patients: a single center experienceGiulia Arrigo, Chiara Frairia, Matilde Scaldaferri et al.|Leukemia & lymphoma/Leukemia and lymphoma|2024Cited by 2
PB2057: THE COMBINATION OF ANTI-COMPLEMENT THERAPY AND CYCLOSPORINE +/- ELTROMBOPAG IN PNH IS EFFECTIVE AND SAFE: A REAL-LIFE OBSERVATIONAL STUDY.Federica Catania, Valentina Giai, Chiara Frairia et al.|HemaSphere|2023Cited by 0
TREATMENT - CURRENT TREATMENT OPTIONS - HIGHER RISK MDSChiara Frairia, Ernesta Audisio, Federica Catania et al.|Leukemia Research|2025Cited by 0